Equities research analysts forecast that Albireo Pharma Inc (NASDAQ:ALBO) will report sales of $1.55 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Albireo Pharma’s earnings, with estimates ranging from $700,000.00 to $3.00 million. The company is scheduled to announce its next quarterly earnings report on Tuesday, November 13th.
On average, analysts expect that Albireo Pharma will report full year sales of $14.62 million for the current fiscal year, with estimates ranging from $11.90 million to $18.93 million. For the next fiscal year, analysts forecast that the firm will report sales of $13.73 million per share, with estimates ranging from $5.00 million to $26.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.24). The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $2.00 million.
A number of equities analysts have recently issued reports on the company. BidaskClub raised Albireo Pharma from a “strong sell” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research downgraded Albireo Pharma from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, August 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $69.00 price target on shares of Albireo Pharma in a research report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Albireo Pharma has an average rating of “Buy” and an average target price of $59.40.
Shares of ALBO stock traded down $0.33 during trading hours on Tuesday, reaching $31.93. 29,607 shares of the company’s stock were exchanged, compared to its average volume of 74,940. The company has a market cap of $373.46 million, a PE ratio of -10.19 and a beta of 1.23. Albireo Pharma has a fifty-two week low of $20.25 and a fifty-two week high of $39.87.
In related news, insider Ronald Harold Wilfred Cooper acquired 788 shares of the company’s stock in a transaction dated Tuesday, August 14th. The shares were purchased at an average cost of $31.85 per share, with a total value of $25,097.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jan Mattsson sold 25,000 shares of the business’s stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $32.26, for a total transaction of $806,500.00. Following the sale, the chief operating officer now directly owns 43,538 shares in the company, valued at $1,404,535.88. The disclosure for this sale can be found here. Corporate insiders own 3.60% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Hartwell J M Limited Partnership grew its holdings in shares of Albireo Pharma by 32.7% during the second quarter. Hartwell J M Limited Partnership now owns 13,400 shares of the biopharmaceutical company’s stock valued at $476,000 after buying an additional 3,300 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Albireo Pharma during the second quarter valued at $118,000. Acadian Asset Management LLC purchased a new stake in shares of Albireo Pharma during the second quarter valued at $165,000. Wells Fargo & Company MN grew its holdings in shares of Albireo Pharma by 282.1% during the fourth quarter. Wells Fargo & Company MN now owns 6,350 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 4,688 shares during the last quarter. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Albireo Pharma during the second quarter valued at $167,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Story: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.